Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by NImmune Biopharma

NImmune Biopharma Acquires Development and Commercialization Rights to Omilancor in Asian Markets
From NImmune Biopharma
Via Business Wire
NImmune Biopharma to Participate in UBS Virtual Biotechnology Private Company Symposium
From NImmune Biopharma
Via Business Wire
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines
From NImmune Biopharma
Via Business Wire
NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)
From NImmune Biopharma
Via Business Wire
NImmune Biopharma Announces Positive Results of Omilancor in Ulcerative Colitis and Crohn’s disease at the American College of Gastroenterology 2023 Annual Scientific Meeting
From NImmune Biopharma
Via Business Wire
NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn’s Disease
From NImmune Biopharma
Via Business Wire
NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline
From NImmune Biopharma
Via Business Wire
Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Treatment of Ulcerative Colitis and Crohn’s Disease
From NImmune Biopharma
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.